Navigation Links
Amylin, Lilly and Alkermes Announce Receipt of Complete Response Letter from FDA for BYDUREON™
Date:10/19/2010

ssed or implied in this press release due to a number of risks and uncertainties, including the risk that BYDUREON may not be approved by the FDA as soon as anticipated or at all; the companies' response to the complete response letter may not be submitted in a timely manner and/or the information provided in such response may not satisfy the FDA; the FDA may request additional information prior to approval; BYETTA and/or the approval of BYDUREON and the revenues generated from these products may be affected by competition; unexpected new data; safety and technical issues; clinical trials not being completed in a timely manner, not confirming previous results, not being predictive of real world use or not achieving the intended clinical endpoints; label expansion requests or NDA filings not receiving regulatory approval; the commercial launch of BYDUREON being delayed; or manufacturing and supply issues. The potential for BYETTA and/or BYDUREON may also be affected by government and commercial reimbursement and pricing decisions, the pace of market acceptance, or scientific, regulatory and other issues and risks inherent in the development and commercialization of pharmaceutical products including those inherent in the collaboration with and dependence upon Amylin, Lilly and/or Alkermes. These and additional risks and uncertainties are described more fully in Amylin's, Lilly's and Alkermes' most recent SEC filings including their Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Amylin, Lilly and Alkermes undertake no duty to update these forward-looking statements.

BYDUREON™ and BYETTA® are trademarks of Amylin Pharmaceuticals, Inc., and Medisorb® is a registered trademark of Alkermes, Inc. 

P-LLY

(i)The International Diabetes Federation Diabetes Atlas. Available at:

SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Alkermes, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led ... a premier and affordable laser tattoo removal experience with ... Brandeis, focus is in providing high quality cosmetic services with cutting ... " Southern California has seen a ...
(Date:1/14/2014)... , Jan. 14, 2014 Animal Emergency Critical Care, a LifeCentre ... Leesburg, Virginia is the first in Loudoun ... Dr. Susan M. Barnes , Medical Director, ... and husband, Dr. Cole Taylor , are avid scuba divers. ...
(Date:1/14/2014)... , Jan. 14, 2014   Oligomerix, Inc. , a ... therapeutics for Alzheimer,s disease (AD) and related neurodegenerative disorders, ... Valhalla, NY as of January ... space at New York Medical College. Oligomerix, ...
Breaking Medicine Technology:Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... ANTONIO, Feb. 28, 2011 Advanced Cell Diagnostics, ... clinical study utilizing RNAscope™ technology to detect human ... of head and neck cancer. HPV status determined ... of patient outcome and highly concordant with that ...
... 2011 PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) ... dividend policy for 2011 and beyond and declared that the four ... be $0.15 per share of common stock.  The $0.15 dividends will ... 15 to all stockholders who own shares of PDL on March ...
Cached Medicine Technology:ACD Announces Clinical Study Results Using its RNAscope™ Technology 2ACD Announces Clinical Study Results Using its RNAscope™ Technology 3PDL BioPharma Announces Regular Quarterly Dividend Policy 2
(Date:4/18/2014)... Medicine scientists could lead to potential new treatments for ... scleroderma. , Fibrosis, or scarring, is a hallmark ... and lungs can lead to serious organ damage and, ... therapeutic options centers on findings made by Swati Bhattacharyya, ... role that a specific protein plays in promoting fibrosis. ...
(Date:4/17/2014)... relief targets that could be used to provide ... College London made the discovery when researching how ... the body. , Dr Marzia Malcangio said: "We ... generation and our findings could help chemotherapy patients ... potential side effect of some chemotherapy drugs (such ...
(Date:4/17/2014)... the University of California, San Diego School of Medicine ... have suffered a recent major loss are more likely ... , The study is published in this month,s issue ... , Because compassionate behaviors are associated with better health ... insights into ways to improve the outcomes of individuals ...
(Date:4/17/2014)... biology team has created a new technology for ... could travel the body and selectively target cancer ... biological devices that monitor and modify human physiology ... However, no existing technology enabled bioengineers to build ... and respond in a customized fashion. , "The ...
(Date:4/17/2014)... (April 16, 2014) The cause of neuronal death ... study proposes that neurons may be mistaken for foreign ... similar to the way autoimmune diseases like type I ... cells. The study was published April 16, 2014, in ... and likely controversial, idea in Parkinson,s disease; but if ...
Breaking Medicine News(10 mins):Health News:New clues on tissue scarring in scleroderma 2Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2
... 2 Bob Hickman, United Feather & Down,s Senior Vice ... Inc.,s Vice President of Marketing, list their top sleep and ... four times faster than water, and its super emollient qualities ... bedding is kind to your skin to help you awaken ...
... , MIAMI, Oct. 2 The American Lung Association of ... Influenza initiative by conducting a public influenza panel discussion ... influenza and the importance of annual vaccination. The meeting will ... among high-risk groups. , The recent A (H1N1) outbreak ...
... Rising Medical Solutions, Inc. (Rising), a leading medical-financial solutions ... Company Index (PCI) "Top 10 Growth Companies" list. This ... honoree, making it the longest running Company to achieve ... , Comments Stephen H. Watkins, CEO of PCI sponsor ...
... , LEE,S SUMMIT, Mo., Oct. 2 R&D/Leverage,s ... integrated under one roof - continue to expand in ... the company,s Vice President - Engineering. , According to ... technical and engineering staff, new lean initiatives and quality-control ...
... LAS VEGAS, Oct. 2 Cord Blood America, Inc. ... cell preservation company ( http://www.cordblood-america.com ) ... cells, a biological insurance policy, to families nationwide and ... principal amount $160,000, in its continuing effort to reduce ...
... World Vision, one of the world,s leading emergency response ... be a wake-up call to the global community to fund ... agency, an expert in disaster risk reduction (DRR), works with ... to disasters like earthquakes and tsunamis, and says that DRR ...
Cached Medicine News:Health News:Ten from Two: Top Sleep and Beauty Tips from the Experts 2Health News:Ten from Two: Top Sleep and Beauty Tips from the Experts 3Health News:American Lung Association of Florida-South Area Encourages Miami Residents to See Themselves Among the Many 'Faces' of Influenza 2Health News:American Lung Association of Florida-South Area Encourages Miami Residents to See Themselves Among the Many 'Faces' of Influenza 3Health News:American Lung Association of Florida-South Area Encourages Miami Residents to See Themselves Among the Many 'Faces' of Influenza 4Health News:American Lung Association of Florida-South Area Encourages Miami Residents to See Themselves Among the Many 'Faces' of Influenza 5Health News:Rising Medical Solutions First to Achieve Six Consecutive Rankings on the Private Company Index 2Health News:R&D/Leverage Heightens Investment in Medical and Silicone Mold Manufacturing 2Health News:R&D/Leverage Heightens Investment in Medical and Silicone Mold Manufacturing 3Health News:Cord Blood America Retires Note in Continuing Effort to Reduce Debt 2Health News:World Vision Says Asian Disasters Should Be 'Wake-Up Call' For Global Leaders 2Health News:World Vision Says Asian Disasters Should Be 'Wake-Up Call' For Global Leaders 3
... SST™ Tubes contain spray-coated ... gel for serum separation. ... serum determinations in chemistry. ... efficient means of serum ...
BD Vacutainer® PST™ Tubes contain spray-coated lithium heparin and a gel for plasma separation. They are used for plasma determinations in chemistry....
MONOJECT Red/Yellow Mottled Stopper...
BD Vacutainer® Specialty Tubes - Thrombin...
Medicine Products: